



SHAREABLE PDF

Allergen inhalation generates pro-inflammatory oxidised phosphatidylcholine associated with airway dysfunction

Christopher D. Pascoe ^{1,2,8}, Aruni Jha ^{1,2,8}, Min Hyung Ryu³, Mirna Ragheb^{1,2}, Jignesh Vaghasiya^{1,2}, Sujata Basu², Gerald L. Stelmack², Sadeesh Srinathan⁴, Biniam Kidane⁴, Jason Kindrachuk⁵, Paul M. O'Byrne ⁶, Gail M. Gauvreau⁶, Amir Ravandi⁷, Christopher Carlsten ³ and Andrew J. Halayko ^{1,2} on behalf of the Canadian Respiratory Research Network

Affiliations: ¹Dept of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB, Canada. ²Biology of Breathing Group, Children's Research Hospital of Manitoba, Winnipeg, MB, Canada. ³Dept of Medicine, University of British Columbia, Vancouver, BC, Canada. ⁴Dept of Surgery, University of Manitoba, Winnipeg, MB, Canada. ⁵Dept of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada. ⁶Dept of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada. ⁷Dept of Medicine, University of Manitoba, Winnipeg, MB, Canada. ⁸Co-first authors.

Correspondence: Andrew J. Halayko, University of Manitoba, Children's Hospital Research Institute of Manitoba, 6th Floor - 715 McDermott Avenue, Winnipeg, MB, Canada. E-mail: Andrew.Halayko@umanitoba.ca



@ERSpublications

Unique profiles of oxidised phospholipids in the human lung correlate with airway pathophysiology. They are novel pro-inflammatory mediators with direct effects in structural cells *via* complex pathways, and are not targeted by standard asthma therapies. <https://bit.ly/34UO2AL>

Cite this article as: Pascoe CD, Jha A, Ryu MH, *et al.* Allergen inhalation generates pro-inflammatory oxidised phosphatidylcholine associated with airway dysfunction. *Eur Respir J* 2021; 57: 2000839 [https://doi.org/10.1183/13993003.00839-2020].

This single-page version can be shared freely online.

ABSTRACT Oxidised phosphatidylcholines (OxPCs) are produced under conditions of elevated oxidative stress and can contribute to human disease pathobiology. However, their role in allergic asthma is unexplored. The aim of this study was to characterise the OxPC profile in the airways after allergen challenge of people with airway hyperresponsiveness (AHR) or mild asthma. The capacity of OxPCs to contribute to pathobiology associated with asthma was also to be determined.

Using bronchoalveolar lavage fluid from two human cohorts, OxPC species were quantified using ultra-high performance liquid chromatography-tandem mass spectrometry. Murine thin-cut lung slices were used to measure airway narrowing caused by OxPCs. Human airway smooth muscle (HASM) cells were exposed to OxPCs to assess concentration-associated changes in inflammatory phenotype and activation of signalling networks.

OxPC profiles in the airways were different between people with and without AHR and correlated with methacholine responsiveness. Exposing patients with mild asthma to allergens produced unique OxPC signatures that associated with the severity of the late asthma response. OxPCs dose-dependently induced 15% airway narrowing in murine thin-cut lung slices. In HASM cells, OxPCs dose-dependently increased the biosynthesis of cyclooxygenase-2, interleukin (IL)-6, IL-8, granulocyte-macrophage colony-stimulating factor and the production of oxylipins *via* protein kinase C-dependent pathways.

Data from human cohorts and primary HASM cell culture show that OxPCs are present in the airways, increase after allergen challenge and correlate with metrics of airway dysfunction. Furthermore, OxPCs may contribute to asthma pathobiology by promoting airway narrowing and inducing a pro-inflammatory phenotype and contraction of airway smooth muscle. OxPCs represent a potential novel target for treating oxidative stress-associated pathobiology in asthma.